Congress Needs To Review “Authorized” Generics, Hatch And Waxman Agree
This article was originally published in The Pink Sheet Daily
Executive Summary
The legislature should consider how “authorized” generics affect the incentive for generic companies to pursue patent challenges, Sen. Hatch (R-Utah) tells a Drug & Device Dialogue audio conference. Rep. Waxman (D-Calif.) says Congress must “revisit” Waxman/Hatch if CMS does not address authorized generics through Medicaid “best price” reporting.